|1.||Hinz, Burkhard: 3 articles (09/2014 - 01/2008)|
|2.||Ramer, Robert: 3 articles (09/2014 - 01/2008)|
|3.||Maslov, L N: 3 articles (01/2007 - 02/2002)|
|4.||Krylatov, A V: 3 articles (01/2007 - 02/2002)|
|5.||Sander, Birgitta: 2 articles (09/2008 - 11/2006)|
|6.||Flygare, Jenny: 2 articles (09/2008 - 11/2006)|
|7.||Christensson, Birger: 2 articles (09/2008 - 11/2006)|
|8.||Gustafsson, Kristin: 2 articles (09/2008 - 11/2006)|
|9.||Pertwee, R G: 2 articles (01/2007 - 02/2002)|
|10.||Makriyannis, A: 2 articles (05/2002 - 02/2002)|
|2.||Status Epilepticus (Complex Partial Status Epilepticus)
03/08/2007 - "Methanandamide and 2-AG inhibited status epilepticus in a dose-dependent manner with an EC(50) of 145+/-4.15 nM and 1.68+/-0.19 microM, respectively. "
03/08/2007 - "These results provide the first evidence that the endocannabinoids, methanandamide and 2-AG, are effective inhibitors of refractory status epilepticus in the hippocampal neuronal culture model and indicate that regulating the endocannabinoid system may provide a novel therapeutic approach for treating refractory status epilepticus."
03/08/2007 - "In addition, the anti-status epilepticus effects of methanandamide and 2-AG were mediated by activation of the cannabinoid CB(1) receptor since they were blocked by the cannabinoid CB(1) receptor antagonist AM251. "
03/08/2007 - "This study evaluated the effects of the major endocannabinoids methanandamide and 2-arachidonylglycerol (2-AG) on status epilepticus in the low-Mg(2+) hippocampal neuronal culture model. "
02/01/2013 - "In the present studies, the effects of CB(1) agonists [(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (AM411), 9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol (AM4054), R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212.2), Δ(9)-tetrahydrocannabinol (Δ(9)-THC), (R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide (methanandamide)], CB(1) antagonists [5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (SR141716A), 5-(4-alkylphenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (AM4113)], and dopamine (DA)-related [methamphetamine, (±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF82958), (R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390), (6aR)-5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo[de,g]quinoline-10,11-diol (R-(-)-NPA), haloperidol] and opioid (morphine, naltrexone) drugs on scheduled-controlled responding under a 30-response fixed ratio schedule of stimulus-shock termination in squirrel monkeys were compared before and during chronic treatment with the long-acting CB(1) agonist AM411 (1.0 mg/kg per day, i.m.). "
|4.||Prostatic Neoplasms (Prostate Cancer)
09/01/2012 - "Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats."
09/01/2012 - "Evidence exists of the anti-inflammatory and immunological properties of endocannabinoids in various tissues; the aim of the present study was therefore to assess the effect of long-term treatment with the synthetic cannabinoid methanandamide (Meth-AEA) on the progression of periodontitis in rats. "
|2.||Cannabinoid Receptors (Cannabinoid Receptor)
|5.||Cyclooxygenase 2 (Cyclooxygenase-2)
|7.||Morphine (MS Contin)